167 related articles for article (PubMed ID: 15125705)
1. Endocrine complications of high-dose therapy with stem cell transplantation.
Sanders JE
Pediatr Transplant; 2004 Jun; 8 Suppl 5():39-50. PubMed ID: 15125705
[TBL] [Abstract][Full Text] [Related]
2. Growth and development after hematopoietic cell transplant in children.
Sanders JE
Bone Marrow Transplant; 2008 Jan; 41(2):223-7. PubMed ID: 17922039
[TBL] [Abstract][Full Text] [Related]
3. Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood.
Bakker B; Oostdijk W; Bresters D; Walenkamp MJ; Vossen JM; Wit JM
Bone Marrow Transplant; 2004 May; 33(10):1049-56. PubMed ID: 15048143
[TBL] [Abstract][Full Text] [Related]
4. Long term effects and quality of life in children and adults after marrow transplantation.
Sanders J; Sullivan K; Witherspoon R; Doney K; Anasetti C; Beatty P; Petersen FB
Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():27-9. PubMed ID: 2697434
[TBL] [Abstract][Full Text] [Related]
5. Late effects in children after bone marrow transplantation: a review.
Locatelli F; Giorgiani G; Pession A; Bozzola M
Haematologica; 1993; 78(5):319-28. PubMed ID: 8314162
[TBL] [Abstract][Full Text] [Related]
6. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen.
Aggarwal C; Gupta S; Vaughan WP; Saylors GB; Salzman DE; Katz RO; Nance AG; Tilden AB; Carabasi MH
Biol Blood Marrow Transplant; 2006 Jul; 12(7):770-7. PubMed ID: 16785066
[TBL] [Abstract][Full Text] [Related]
7. [Analysis of some risk factors for abnormal growth velocity in children treated with haematopoetic stem cell transplantation].
Wójcik D; Barg E; Niedzielska E; Doroszko A; Kałwak K; Pietras W
Med Wieku Rozwoj; 2006; 10(3 Pt 1):841-8. PubMed ID: 17317915
[TBL] [Abstract][Full Text] [Related]
8. A myeloablative conditioning regimen for patients with impaired cardiac function undergoing allogeneic stem cell transplantation: reduced cyclophosphamide combined with etoposide and total body irradiation.
Yoshimi A; Nannya Y; Sakata-Yanagimoto M; Oshima K; Takahashi T; Kanda Y; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Aug; 83(8):635-9. PubMed ID: 18506704
[TBL] [Abstract][Full Text] [Related]
9. Endocrinological late complications after hematopoietic SCT in children.
Cohen A; Békássy AN; Gaiero A; Faraci M; Zecca S; Tichelli A; Dini G;
Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S43-8. PubMed ID: 18545244
[TBL] [Abstract][Full Text] [Related]
10. Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.
Beelen DW; Trenschel R; Casper J; Freund M; Hilger RA; Scheulen ME; Basara N; Fauser AA; Hertenstein B; Mylius HA; Baumgart J; Pichlmeier U; Hahn JR; Holler E
Bone Marrow Transplant; 2005 Feb; 35(3):233-41. PubMed ID: 15592494
[TBL] [Abstract][Full Text] [Related]
11. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
12. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
13. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
14. Endocrine complications of hematopoietic stem cell transplantation.
Chemaitilly W; Sklar CA
Endocrinol Metab Clin North Am; 2007 Dec; 36(4):983-98; ix. PubMed ID: 17983932
[TBL] [Abstract][Full Text] [Related]
15. BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma.
Talamo G; Claxton DF; Dougherty DW; Ehmann CW; Sivik J; Drabick JJ; Rybka W
Bone Marrow Transplant; 2009 Aug; 44(3):157-61. PubMed ID: 19204716
[TBL] [Abstract][Full Text] [Related]
16. [Alterations in coagulation in patients during transplant conditioning regimen before allogeneic hematopoietic stem cell transplantation].
Jiang Q; Huang XJ; Liu KY; Chen H; Chen YH; Gao ZY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Mar; 27(3):173-7. PubMed ID: 16792919
[TBL] [Abstract][Full Text] [Related]
17. Comparative outcome of hematopoietic stem cell transplantation for pediatric acute lymphoblastic leukemia following cyclophosphamide and total body irradiation or VP16 and total body irradiation conditioning regimens.
Gassas A; Sung L; Saunders EF; Doyle JJ
Bone Marrow Transplant; 2006 Dec; 38(11):739-43. PubMed ID: 17013424
[TBL] [Abstract][Full Text] [Related]
18. Disturbance of pubertal development after cancer treatment.
Müller J
Best Pract Res Clin Endocrinol Metab; 2002 Mar; 16(1):91-103. PubMed ID: 11987901
[TBL] [Abstract][Full Text] [Related]
19. Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases.
Somali M; Mpatakoias V; Avramides A; Sakellari I; Kaloyannidis P; Smias C; Anagnostopoulos A; Kourtis A; Rousso D; Panidis D; Vagenakis A
Gynecol Endocrinol; 2005 Jul; 21(1):18-26. PubMed ID: 16048797
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
